New Jersey A4550 mandates health insurance coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or.
New Jersey A4550 requires health insurers to cover expenses for buprenorphine and buprenorphine/naloxone for pain treatment. The bill applies to various health insurance policies and contracts, including those issued by health, hospital, and medical service corporations, health maintenance organizations, and health benefits plans. It prohibits insurers from using step therapy or fail-first protocols, which may require patients to use riskier, more addictive drugs before using buprenorphine or buprenorphine/naloxone. The act takes effect 90 days after enactment.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.